Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 13Neoplasms 11Neoplasm Metastasis 11Rectal Neoplasms 6Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Cancer Metastatic 4Colonic Neoplasms 4Carcinoma, Ovarian Epithelial 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Prostatic Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2Sarcoma 2Penile Neoplasms 2

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors × aflibercept × Clear all
NCT01688960 2015-03-17

Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
48 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡